natgillin/translations-raw huggingface dataset:
Anden månedlige vejning hvor vægttabet er <3 % pr. måned siden sidste vejning.
Second monthly weighing where bodyweight loss < 3% per month since previous weighing
Anden non-hæmatologisk toksicitet (eksklusive metaboliske bivirkninger)
Other non-haematologica l toxicities (excluding metabolic events)
Anden primær malignitet
Second Primary Malignancies
Anden rapporteret, klinisk erfaring har ikke identificeret forskelle i respons mellem ældre og yngre patienter, men større følsomhed hos nogle ældre personer kan ikke udelukkes (se pkt.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see section 5.2).
Anden samtidig medicin med klinisk relevans
Other concomitant medicinal products of clinical relevance
anden samtidig sygdom (f.eks. opkastning, diarré),
intercurrent illness (e.g. vomiting, diarrhoea),
Anden samtidig sygdom, især infektioner og febertilstande , øger normalt patientens insulinbehov.
Concomitant illness, especially infections and feverish conditions, usually increases the patient’s insulin requirement.
Anden samtidig sygdom, især infektioner og febertilstande, øger normalt patientens insulinbehov.
Concomitant illness, especially infections and feverish conditions, usually increases the patient’s insulin requirement.
Anden samtidig sygdom, især infektioner og tilstande med feber øger normalt patientens insulinbehov.
Concomitant illness, especially infections and feverish conditions, usually increases the patient’s insulin requirements.
Anden samtidig sygdom, især infektioner og tilstande med feber, øger normalt patientens insulinbehov.
Concomitant illness, especially infections and feverish conditions, usually increases the patient’s insulin requirements.
Anden samtidig sygdom, især infektioner, og tilstande med feber øger normalt patientens insulinbehov.
Concomitant illness, especially infections and feverish conditions, usually increases the patient’s insulin requirements.
anden smerte, herunder i hals, nakke eller skulder
other pain, including neck, shoulder or throat pain
Anden særlig population
Other special population
Anden TIMI Major
Other TIMI Major
Anden vaccination - mellem 6 og 12 måneder efter den første vaccination.
The second injection – between 6 and 12 months after the first injection.
Anden vaccination: Ved 17 dages alderen.
Second vaccination: at 17 days of age.
Anden- eller tredjegrads-atrioventrikulær blok
Second- or third-degree atrioventricular blocks
Andengradsforbrændinger, utilsigtet eksponering (herunder øjensmerter, øjen- og halsirritation samt hoste)
Burns second degree, accidental exposure (including eye pain, eye and throat irritation and cough)
Andere allelen die in verband worden gebracht met een afwezig of verminderd metabolisme komen minder vaak voor en omvatten CYP2C19*4, *5,
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5,
Andere bijwerkingen zijn:
Other side effects include:
Andere geneesmiddelen:
Other medicinal products:
ANDERE VOORWAARDEN EN EISEN DIE DOOR DE HOUDER VAN DE HANDELSVERGUNNING MOETEN WORDEN NAGEKOMEN
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
AndersonBrecon (UK) Limited, (Trading as PCI) Units 2-7, Wye Valley Business Park
Units 2-7, Wye Valley Business Park Brecon Road, Hay-on-Wye, Hereford HR3 5PG
ANDET
5.
Andet
88.6
ANDET
LABELLING
ANDET (FOR KALENDERPAKNINGER)
OTHER (FOR CALENDARISED PACKS)
ANDET (FORKALENDERPAKNINGER)
OTHER (FOR CALENDARISED PACKS)
ANDET (FORKORTELSER FOR UGEDAGE TIL KALENDERPAKNINGER)
OTHER (FOR CALENDARISED PACKS)
ANDET (KUN FOR KALENDERISEREDE PAKNINGSSTØRRELSER MED 14, 28, 56, 84 OG 98 TABLETTER)
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Andet 1 0
Other 1 0
Andet 4/297 1,3
Other 4/297 1.3
Andet doseringstrin (0,5 ml) til behandlingsdagene 7, 9, 11 Del af en titreringspakning.
2nd dosage step (0.5 ml) for treatment days 7, 9, 11 Part of a titration pack.
ANDET FORKALENDERPAKNINGER)
OTHER (FOR CALENDARISED PACKS)
andet materiale klæber til det det er anden gang, at det løsner sig eller falder af.
it has other material stuck to it it is the second time it has become loose or has fallen off.
Andet og tredje trimester af graviditet (se pkt.
Second and third trimester of pregnancy (see section 4.6).
Andet omfatter patienter med detekterbart HCV RNA på det faktiske tidspunkt for behandlingsafslutning, men som ikke opfyldte definitionen af virologisk svigt under behandlingen, samt patienter med manglende HCV RNA- vurdering under den planlagte opfølgning.
Other includes patients with detectable HCV RNA at their actual end of treatment but who did not meet the definition of on-treatment virologic failure, and patients with a missing HCV RNA assessment during planned follow-up.
Andet omfatter patienter, der ikke opnåede SVR og ikke opfyldte kriterierne for virologisk svigt (f.eks. lost to follow-up).
Other includes patients who did not achieve SVR and did not meet virologic failure criteria (e.g. lost to follow-up).
Andet omfatter patienter, der ikke opnåede SVR og ikke opfyldte kriterierne for virologisk svigt (f.eks. opfølgning mangler).
Other includes patients who did not achieve SVR and did not meet virologic failure criteria (e.g. lost to follow-up).
Andet omfatter patienter, der ikke opnåede SVR12 og ikke opfyldte kriterierne for virologisk svigt (f.eks. lost to follow-up).
Other includes subjects who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).
Andet omfatter patienter, der ikke opnåede SVR12 og ikke opfyldte kriterierne for virologisk svigt.
Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria.
Andet omfatter personer, der ikke opnåede SVR12 og ikke opfyldte kriterierne for virologisk svigt (f.eks. lost to follow-up).
Other includes subjects who did not achieve SVR12 and did not meet virologic failure criteria (e.g., lost to follow-up).
Andet trimester af graviditeten (n=11)a
Second trimester of pregnancy (n=11)a
Andet trimester af graviditeten (n=16)
Second trimester of pregnancy (n=11)a
Andet trimester af graviditeten (n=16)
Second trimester of pregnancy (n=16)
ANDET – Tekst på indersiden af låget
OTHER – Printing on inside of lid
Andet: dobbeltblokade af renin-anfiotensin-aldosteronsystemet (RAAS)
Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)
Andet: Hyppig vandladning, blod i urinen, nakkesmerter, rygsmerter, brystsmerter, muskelspændthed eller kramper, hævede led, ubehag i arme og ben, muskelsvækkelse, gigtbetændelse og gigtsmerter
Other: frequent urination, blood in urine, neck pain, back pain, breast pain, muscle tightness or cramps, joint swelling, limb discomfort, muscle weakness, arthritis inflammation and pain
Andet: Kulderystelser, vægttab, hævelse i særlige områder og smerter i muskler og knogler
Other: chills, weight decrease, swelling in specific areas and muscle bone pain
Andeta
Othera
Andetb
Otherb
Andetc
Other
Andetc
Otherc
Andet‡
Other
Andr e bivir kninger , der er set med Rivasigmin Teva depotplaster , og som kan for ekomme ved br ug af hår de kapsler :
Other side effects seen with Rivastigmine transdermal patches and which may occur with hard capsules:
Andre
Interactions
ANDRE
MISCELLANEOUS
Andre (cimitiden, warfarin, furosemid, digoxin, atenolol, indometacin, hydrochlorthiazid, amlodipin, glibenclamid)
Others (cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide)
Andre 17% viste ikke de 0,5 IE/ml rabies antistof-titer, som er påkrævet i nogle ikke-EU lande ved indrejse.
Another 17% did not show the 0.5 IU/ml rabies antibody titre required by some non-EU countries to travel in.
Andre abnorme laboratorieværdier
Other laboratory abnormalities
Andre administrationsmåder end i.v. og i.m. (f.eks. intra-artikulær, intratekal) er ikke undersøgt og bør derfor ikke anvendes.
Modes of administration other than IV or IM (e.g. intra-articular, intrathecal) have not been studied and should not be used.
Andre aktivatorer af det innate immunsystem som endogene agonister af toll-lignende receptorer kan medvirke til transkriptionel aktivering af IL-1 beta-genet, hvorved et anfald af urinsyregigt igangsættes.
Other activators of the innate immune system, such as endogenous agonists of toll-like receptors, may contribute to the transcriptional activation of the IL- 1 beta gene, initiating a gouty arthritis attack.
Andre aktive stoffer såsom cimetidin, ranitidin, procainamid, quinidin, quinin og nicotin, der bruger samme renale kationiske transportsystem som amantadin, kan muligvis også have interaktion med memantin, hvilket kan medføre en potentiel risiko for forhøjede plasmaniveauer.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Andre aktive stoffer såsom cimetidin, ranitidin, procainamid, quinidin, quinin og nicotin, der bruger samme renale kationiske transportsystem som amantadin, kan muligvis også have interaktion med memantin, hvilket kan medføre en risiko for forhøjede plasmaniveauer.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Andre aktive stoffer såsom cimetidin, ranitidin, procainamid, quinidin, quinin og nikotin, der bruger samme renale kationiske transportsystem som amantadin, kan muligvis også have interaktion med memantin, hvilket kan medføre en potentiel risiko for forhøjede plasmaniveauer.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Andre aktive stoffer såsom cimetidin, ranitidin, procainamid, quinidin, quinin og nikotin, der bruger samme renale kationiske transportsystem som amantadin, kan muligvis også have interaktion med memantin, hvilket kan medføre en risiko for forhøjede plasmaniveauer.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Andre aktive stoffer såsom cimetidin, ranitidin, procainamid, quinidin, quinin og nikotin, der bruger samme renale kationiske transportsystem som amantadin, kan muligvis også have interaktion med memantin, hvilket kan medføre en risiko for forhøjede plasmaniveauer.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine andnicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Andre aktive stoffer såsom cimetidin, ranitidin, procainamid, quinidin, quinin og nikotin, der bruger samme renale kationiske transportsystem som amantadin, kan muligvis også have interaktion med memantin, hvilket kan medføre en risiko for forhøjede plasmaniveauer.
Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine andnicotine that use the same renal cationic transport system as amantadine may also possiblyi nteract with memantine leading to a potential risk of increased plasma levels.
Andre aktivstoffer: Ethanol, vandfri 150 mg/ml.
Other substances: Ethanol anhydrous 150 mg/ml.
Andre alleler, der associeres med manglende eller nedsat metabolisme er mindre hyppige og inkluderer CYP2C19*4, *5, *6, *7 og *8.
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5,
Andre allergiske reaktioner med hævelse af ansigt eller hals
Other allergic reactions with swelling of the face or throat
Andre allergiske reaktioner som piben i lungerne, hævelser eller følelse af svimmelhed
Other allergic reactions, such as wheezing, swelling or feeling light-headed
andre allergiske reaktioner træthed
other allergic reactions tiredness
Andre almindelige (> 1%) bivirkninger er rødmen, varmefølelse, smerte, øget hudfølsomhed (specielt for kulde og varme), prikken i huden, hududslæt, folliculitis (inflammerede eller inficerede hårsække) og herpes virus infektioner (f.eks. forkølelsessår, udbredte herpes simplex infektioner).
( 1%) side effects are redness, feeling of warmth, pain, increased skin sensitivity (especially to hot and cold), skin tingling, rash, folliculitis (inflamed or infected hair follicles) and herpes viral infections (e.g. cold sores, generalised herpes simplex infections).
Andre almindelige (> 1%) bivirkninger er rødmen, varmefølelse, smerte, øget hudfølsomhed (specielt for kulde og varme), prikken i huden, hududslæt, folliculitis (inflammerede eller inficerede hårsække) og herpes virus infektioner (f.eks. forkølelsessår, udbredte herpes simplex infektioner).
Other common ( 1%) side effects are redness, feeling of warmth, pain, increased skin sensitivity (especially to hot and cold), skin tingling, rash, folliculitis (inflamed or infected hair follicles) and herpes viral infections (e.g. cold sores, generalised herpes simplex infections).
Andre almindelige bivirkninger (som forekommer hos op til 1 ud af 10 patienter) er hypokalcæmi og hypofosfatæmi (for lavt calcium- eller fosfatindhold i blodet), forøget svedafsondring, tab af tænder og osteonekrose i kæben(beskadigelse af knoglerne i kæben, som kan medføre smerter, sår i munden eller løsning af tænder.
Other common side effects (seen in up to 1 patient in 10) are hypocalcaemia and hypophosphataemia (low levels of calcium or phosphate in the blood), excessive sweating, tooth loss and osteonecrosis in the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth).
Andre almindelige bivirkninger er sløvhed, nedsat appetit, diarré, kløe (pruritus), inflammation af huden (dermatitis), og rødme af hud og ører.
Other common side effects include lethargy (sluggishness), decreased appetite, diarrhoea, pruritus (itching), dermatitis (inflammation of the skin) and reddening of the skin and ear.
Andre almindelige bivirkninger er unormal nyrefunktion og unormal blodtælling (røde blodlegemer, hvide blodlegemer og blodplader).
Other common side effects include abnormal kidney function and blood cell counts (red cells, white cells and platelets).
Andre almindelige bivirkninger:
Other common side effects:
Andre almindelige symptomer er: kvalme, opkastning, diarré, mavesmerter og udtalt træthed.
Other common symptoms are: nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness
Andre almindelige symptomer:
Other common symptoms are:
Andre almindelige symptomer: kvalme, opkastning, diarré, mavesmerter, udtalt træthed.
Other common symptoms are: nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness
Andre almindelige øjenrelaterede bivirkninger indberettet, som muligvis at være forårsaget af lægemidlet eller indsprøjtningsmåden, omfatter:
Other common eye side effects reported to be possibly caused by the medicine or by the injection procedure include:
Andre almindeligt forekommende lægemiddelreaktioner var mundtørhed (8,6 %), forstoppelse (3,9 %), diarré (3,2 %), hovedpine (3,0 %), svimmelhed (2,3 %) og sløret syn (2,3 %).
Other commonly occurring adverse drug reactions reported were dry mouth (8.6%), constipation (3.9%), diarrhoea (3.2%), headache (3.0%), dizziness (2.3%) and blurred vision (2.3%).
Andre almindeligt observerede bivirkninger var i de fleste tilfælde lette eller moderate.
Other commonly observed adverse reactions were in most cases mild or moderate:
Andre almindeligt sete bivirkninger hos katte var diarré og appetitløshed.
Other commonly observed adverse reactions in cats were diarrhoea and anorexia.
Andre alvorlige bivirkninger
Other serious side effects
Andre alvorlige bivirkninger fra disse 3 studier omfattede infektioner såsom neutropen sepsis (0,8 %) og pneumoni (2,5 %) (nogle med dødeligt udfald), trombocytopeni (3,5 %), overfølsomhedsreaktioner (0,25 %) og blødninger (f.eks. cerebral blødning [0,5 %], mave-tarm-blødning [0,8 %] og intrakraniel blødning [0,5 %]).
Other serious adverse reactions from these 3 studies included infections such as neutropenic sepsis (0.8%) and pneumonia (2.5%) (some with fatal outcome), thrombocytopenia (3.5%), hypersensitivity reactions (0.25%) and haemorrhagic events (e.g. cerebral haemorrhage [0.5%], gastrointestinal haemorrhage [0.8%] and intracranial haemorrhage [0.5%])).
Andre alvorlige bivirkninger identificeret i STS-studierne omfatter venøse tromboemboliske bivirkninger, påvirkning af funktionen af venstre ventrikel og pneumothorax.
Other important serious adverse reactions identified in STS trials included venous thromboembolic events, left ventricular dysfunction and pneumothorax.
Andre alvorlige bivirkninger, som er almindeligt set (dvs. hos 1-10% af hundene) inkluderer: opkastning, diarré, spisevægring, sløvhed, væskemangel, vævshenfald af hud, feber, blod i afføring/blodig diarré/maveblødning og mavesår, kvalme, blodforgiftning, vægttab, øget alaninaminotransferase og nedsat indhold af røde blodlegemer i blodet.
There were other side effects that are seen commonly (i.e. in 1% – 10% of dogs ) which have severe effects, these are vomiting, diarrhoea, anorexia, lethargy, dehydration, skin necrosis, fever, blood in faeces/hemorrhagic diarrhoea/gastrointestinal bleeding and ulcers, nausea, septicaemia, weight loss, increased alanine aminotransferase and decreased haematocrit.
Andre alvorlige hændelser registreret som relateret til eller muligvis relateret til behandling med topotecan blev observeret hos ≥1 % af patienterne og omfattede anoreksi (12 %), utilpashed (3 %) og hyperbilirubinæmi (1 %).
Other severe events occurring in patients that were recorded as related or possibly related to topotecan treatment were anorexia (12 %), malaise (3 %) and hyperbilirubinaemia (1 %).
Andre alvorlige hændelser registreret som relateret til eller muligvis relateret til behandling med topotecan blev observeret hos ≥1 % af patienterne og omfattede anoreksia (12 %), utilpashed (3 %) og hyperbilirubinæmi (1 %).
Other severe events occurring in patients that were recorded as related or possibly related to topotecan treatment were anorexia (12 %), malaise (3 %) and hyperbilirubinaemia (1 %).
Andre alvorlige hændelser registreret som relateret til eller muligvis relateret til behandling med topotecan blev observeret hos  1 % af patienterne og omfattede anoreksi (12 %), utilpashed (3 %) og hyperbilirubinæmi (1 %).
Other severe events occurring in patients that were recorded as related or possibly related to topotecan treatment were anorexia (12 %), malaise (3 %) and hyperbilirubinaemia (1 %).
Andre alvorlige reaktioner ( ikke kendt, hyppigheden kan ikke bestemmes ud fra de tilgængelige data): Gulfarvning af hud og øjne (på grund af alvorlig leverskade) eller nyreproblemer så som smertefuld vandladning og smerter i den nedre del af ryggen kombineret med feber.
Other serious reactions (frequency not known): yellowing of the skin and eyes (due to severe liver damage), or kidney problems such as painful urination and lower back pain with fever.
Andre anbefalinger
Other recommendations
Andre anti-infektiva
Other Anti-infectives
andre antidepressiva (fx venlafaxin og tryptophan) til behandling af svær depression
other anti-depressants (such as venlafaxine and tryptophan) used in major depression tricyclic’s (such as clomipramine and amitriptyline) used for depressive illness
Andre antidepressiva:
Other antidepressants:
Andre antiepileptika, såsom carbamazepin, oxcarbazepin og phenytoin, der anvendes til at behandle anfald, kan påvirke Fycompa.
Other anti-epileptic medicines, such as carbamazepine, oxcarbazepine, and phenytoin that are used to treat fits may affect Fycompa.
Andre antihypertensiva
Other anti-hypertensive drugs
Andre antihypertensiva
Other anti-hypertensive medicinal products
Andre antihypertensiva
Other antihypertensive medicinal products
Andre antihypertensiva Thiazider øger den antihypertensive virkning af andre antihypertensiva (fx guanethidin, methyldopa, betablokkere, vasodilatorer, calciumantagonister, ACE- hæmmere, angiotensin II-antagonister (ARBer) og direkte reninhæmmere [DRIer]).
Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors [DRIs]).
Andre antihypertensiva: Rasilez HCT's antihypertensive virkning kan øges ved samtidig brug af andre antihypertensiva.
Other antihypertensive agents: The antihypertensive effect of Rasilez HCT may be increased with the concomitant use of other antihypertensive agents.
Andre antihypertensive lægemidler der påvirker renin-angiotensin-aldosteronsystemet (RAAS)
Other antihypertensive agents acting on the renin-angiotensin-aldosterone system (RAAS)
Andre antihypertensive lægemidlerder påvirker renin-angiotensin-aldosteronsystemet (RAAS)
Other antihypertensive agents acting on the renin-angiotensin-aldosterone system (RAAS)
Andre antiparkinsonmidler: Indtil nu har der ikke været tegn på interaktioner, der vil udelukke samtidig brug af standard-antiparkinson-lægemidler med Corbilta-behandling.
Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Corbilta therapy.
Andre antiparkinsonmidler: Indtil nu har der ikke været tegn på interaktioner, der vil udelukke samtidig brug af standard-antiparkinson-lægemidler med Levodopa/Carbidopa/Entacapone Orion- behandling.
Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Levodopa/Carbidopa/Entacapone Orion therapy.
Andre antiparkinsonmidler: Indtil nu har der ikke været tegn på interaktioner, der vil udelukke samtidig brug af standard-antiparkinson-lægemidler med Levodopa/Carbidopa/Entacapone Orionbehandling.
Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with
Andre antiparkinsonmidler: Indtil nu har der ikke været tegn på interaktioner, der vil udelukke samtidig brug af standard-antiparkinson-lægemidler med Stalevo-behandling.
Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Stalevo therapy.
Andre antiretrovirale lægemidler
Other antiretroviral medicinal products
Andre antiretrovirale stoffer: På grund af manglende data kan der ikke gives specifikke rekommandationer for andre antiretrovirale stoffer.
Other antiretroviral agents: no specific recommendation can be made with regard to other available antiretroviral agents due to the lack of data.
Andre antivirale midler
Other antiviral agents
Andre antivirale stoffer
Other Antiviral Agents
Andre arter
Other types
Andre associerede manifestationer omfattede lymfadenopati, unormale leverfunktionsprøver og hæmaturi.
Other associated manifestations included lymphadenopathy, liver function tests abnormalities, and haematuria.
Andre autoimmune tilstande
Other autoimmune conditions
Andre baseline-faktorer hos co- inficerede patienter, som kan associeres med en højere risiko for hepatisk dekompensering, inkluderer behandling med didanosin og forhøjet bilirubin serumkoncentration.
Other baseline factors in co-infected patients that may be associated with a higher risk of hepatic decompensation include treatment with didanosine and elevated bilirubin serum concentration.